🌟 June is Myasthenia Gravis Awareness Month! 🌟

Did you know that patients with seronegative myasthenia gravis (snMG) face unique and often greater challenges than those with other forms of MG?

🔍 An April 2025 research study shows:
• snMG patients experience longer diagnostic delays and earlier symptom onset
• Only 15.9% achieve complete remission (compared to 27.8% of AChR-ab+ MG patients)
• They report more severe symptoms, higher fatigue, and greater impact on daily life and employment
🔗The link to the research paper is in the comments.

Clinakos Inc. offers AI-powered, patient-centric Integrated Patient Data™ capabilities that enable insights and research in Myasthenia Gravis that include:
📈 Real-world data on disease progression, integrating lab markers and validated quality of life measures like MG-ADL and QMG, to track patient status over time.
🩺 Comprehensive visibility into all healthcare providers involved—including neurologists, ophthalmologists, endocrinologists, and other specialists.
💊 Detailed analysis of steroid burden, helping to monitor long-term treatment impact and optimize therapy plans.
💡 Actionable insights into treatment patterns, supporting better clinical decisions and improved patient outcomes.

We are passionate and committed to advancing patient-centered research and supporting the MG community with data-driven insights and innovation.💡

👉To know more, reach out to us [https://lnkd.in/gp3gUmXc]
👉Follow us at Clinakos Inc..